Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$17,500.00
Development of Targeted Therapies for the Treatment of Mixed Lineage Leukemia
FY 2021-22
Summary
Disruptor of telomeric silencing 1-like (DOT1L) is a histone methyltransferase, a protein that adds hydrogen atoms onto the amino acid lysine 79 on histone H3. In normal physiological conditions, methylation by DOT1L leads to increased gene expression, this regulation of gene expression plays an important role in several physiological processes and has a positive association with cardiac health and bone health, DOT1L is also important in development and DNA. Unfortunately, DOT1L is associated with health conditions including Mixed Lineage Leukaemia (MLL). Abnormal recruitment of DOT1L to genes associated with MLL leads to increased expression of these genes and subsequent leukemogenesis. Due to DOT1L's association with MLL, plenty of research has, and still is, being done on DOT1L inhibition as a therapy option. However, inhibition of DOT1L is problematic as inhibitors will affect the expression of all the genes regulated by DOT1L, not only the genes associated with MLL, resulting in an increased risk of off-target effects. My Master's project will involve developing, and testing, a new method of selective DOT1L inhibition that will help prevent off-target effects. In order for the inhibitor to stop DOT1L at the site of interest only, the inhibitor will be attached to a chain of Locked Nucleic Acids (LNA) that is complementary to the genes associated with MLL, keeping the inhibitor in place. Inhibition efficacy will be determined by analyzing changes in expression of the MLL associated genes, potential of off-target effects will be determined by analyzing changes in expression of other DOT1L regulated genes. My project will hopefully lead to therapies that are not only efficacious but have no off-target effects as well.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
467032
Name
Hendrickson-Rebizant Thordur D
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of Targeted Therapies for the Treatment of Mixed Lineage Leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Dot1l; Epigenetics; Lc-Ms/Ms; Locked Nucleic Acids; Mixed Lineage Leukaemia; Pleiotropic/Off-Target Effects; Post Translational Histone Modifications; Therapeutics
Abstract
Disruptor of telomeric silencing 1-like (DOT1L) is a histone methyltransferase, a protein that adds hydrogen atoms onto the amino acid lysine 79 on histone H3. In normal physiological conditions, methylation by DOT1L leads to increased gene expression, this regulation of gene expression plays an important role in several physiological processes and has a positive association with cardiac health and bone health, DOT1L is also important in development and DNA. Unfortunately, DOT1L is associated with health conditions including Mixed Lineage Leukaemia (MLL). Abnormal recruitment of DOT1L to genes associated with MLL leads to increased expression of these genes and subsequent leukemogenesis. Due to DOT1L's association with MLL, plenty of research has, and still is, being done on DOT1L inhibition as a therapy option. However, inhibition of DOT1L is problematic as inhibitors will affect the expression of all the genes regulated by DOT1L, not only the genes associated with MLL, resulting in an increased risk of off-target effects. My Master's project will involve developing, and testing, a new method of selective DOT1L inhibition that will help prevent off-target effects. In order for the inhibitor to stop DOT1L at the site of interest only, the inhibitor will be attached to a chain of Locked Nucleic Acids (LNA) that is complementary to the genes associated with MLL, keeping the inhibitor in place. Inhibition efficacy will be determined by analyzing changes in expression of the MLL associated genes, potential of off-target effects will be determined by analyzing changes in expression of other DOT1L regulated genes. My project will hopefully lead to therapies that are not only efficacious but have no off-target effects as well.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hendrickson-Rebizant, Thordur D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~